Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors

Alexandre Vivot (1) , Perrine Créquit (2) , Raphaël Porcher (3)

1 CRESS (U1153 / UMR_A_1125 / UMR_S_1153) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité
2 CHU Tenon [AP-HP]
3 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)

Domaines: Sciences du Vivant [q-bio]; Cancer

Alexandre Vivot, Perrine Créquit, Raphaël Porcher. Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors. JNCI: Journal of the National Cancer Institute, 2019, 111 (5), pp.519-521. ⟨10.1093/jnci/djy211⟩. ⟨hal-02268387⟩